Form 4: Verona Pharma Executive Cashes Out in Merger

Verona Pharma's Chief Medical Officer, Kathleen A. Rickard, disposed of all her beneficial ownership in the company's shares and derivative securities following a scheme of arrangement related to an acquisition.

Summary

• Kathleen A. Rickard, Chief Medical Officer of Verona Pharma plc (VRNA), reported transactions related to a Scheme of Arrangement under the UK Companies Act 2006.
• The Scheme of Arrangement was pursuant to a Transaction Agreement dated July 8, 2025, involving Verona Pharma plc, Merck Sharp & Dohme LLC, and Vol Holdings LLC.
• At the effective time of the Scheme of Arrangement, holders of Scheme Shares became entitled to receive $13.375 in cash per Scheme Share.
• Holders of American Depositary Shares (ADSs) received $107 in cash per ADS, as each ADS represents eight Ordinary Shares.
• Ms. Rickard disposed of 2,432,868 Ordinary Shares and subsequently acquired and disposed of 1,131,984 Ordinary Shares, resulting in 0 Ordinary Shares beneficially owned.
• Outstanding time-based Restricted Share Unit (RSU) awards and Performance-Based Restricted Share Unit (PRSU) awards became fully vested and were converted into cash based on the ADS Consideration.
• Share options with an exercise price less than the ADS Consideration also became fully vested and were converted into cash.
• Ms. Rickard's derivative securities, including RSUs (146,168, 167,056, 200,000, and 618,760) and Share Options (560,000 at $0.75, 100,000 at $0.71), were converted to cash, resulting in 0 derivative securities beneficially owned.

Sentiment

Score: 8

Explanation: The sentiment is highly positive for shareholders and equity holders of Verona Pharma plc, as the filing confirms the successful completion of an acquisition that provides a cash exit at a premium. For the company as an independent entity, it marks the end of its public trading life, which is a neutral outcome in this context.

Positives

• The acquisition provides a clear cash exit for shareholders and equity holders at a specified price of $13.375 per Ordinary Share or $107 per ADS.
• The Chief Medical Officer's equity awards (RSUs, PRSUs, and options) became fully vested and were converted into cash, indicating a successful liquidity event for the executive.

Negatives

• The company, Verona Pharma plc, will no longer operate as an independent publicly traded entity following the acquisition.

Risks

• The filing does not introduce new risks for the ongoing operations of Verona Pharma plc, as it primarily reports the outcome of an acquisition. The primary risk related to the reported transactions was the successful completion of the Scheme of Arrangement, which appears to have occurred.

Future Outlook

The filing indicates the completion of an acquisition of Verona Pharma plc, implying that the company will no longer have an independent future outlook as a publicly traded entity. No forward-looking statements for the acquired entity are provided.

Industry Context

This filing reflects a common event in the pharmaceutical and biotechnology industry: the acquisition of a smaller company by a larger pharmaceutical entity. Such acquisitions often involve the conversion of existing equity and equity awards into cash for the target company's shareholders and executives.

Comparison to Industry Standards

• The conversion of executive equity awards (RSUs, PRSUs, and options) into cash upon a change of control, such as an acquisition, is a standard practice in M&A transactions across industries, particularly in biotech where such awards are a significant part of compensation.
• The structure of the acquisition via a Scheme of Arrangement under UK law is a common legal mechanism for corporate takeovers in the UK, similar to mergers in the U.S.

Stakeholder Impact

• Shareholders: Received $13.375 per Ordinary Share or $107 per ADS in cash, representing a liquidity event.
• Employees (specifically the Chief Medical Officer): Equity awards were converted to cash, providing a financial benefit from the acquisition.

Next Steps

• The filing reports transactions that have already occurred as a result of the Scheme of Arrangement. No further specific actions or milestones for Verona Pharma plc as an independent entity are mentioned.

Key Dates

Keywords

Verona Pharma, VRNA, SEC Form 4, Insider Transaction, Acquisition, Merger, Scheme of Arrangement, Merck Sharp & Dohme, Restricted Share Units, Share Options, Executive Compensation, Cash Out